Clinical Trials

This phase one trial will study the monoclonal antibody BGB-A317 alongside Pamiparib.
More details

This study looks at anti-HER2 therapy plus endocrine therapy with or without palbociclib in patients with hormone receptor-positive HER2+ metastatic breast cancer.
More details

An observational study of how well the thymine loading test can identify patients who cannot tolerate fluoropyrimidine treatment. This study builds upon the first THYMINE Study.
More details

The purpose of this phase II trial is to test whether giving two types of breast cancer treatment (chemotherapy and hormone treatment) at the same time is more effective than giving them one after the other (which is usually done). 
More details

This randomised study compares radiation therapy with observation only, following breast conserving surgery and planned endocrine therapy in patients with stage I breast cancer.
More details

This phase 2 clinical trial is looking into lymph node grafting for upper limb lymphoedema following breast cancer treatment.
More details

This study will evaluate the safety and efficacy of the drug, Abemaciclib, in participants with high risk, node positive, early stage, hormone receptor positive, HER2-negative breast cancer.
More details

The New Zealand Familial Breast Cancer Study commenced in 2013 with the key goal of better understanding DNA sequence changes in genes that alter the risk of developing breast cancer 
More details

The PantoCIN trial will test the ability of a cheap, widely available drug to prevent two of chemotherapy’s most unpleasant side-effects: delayed nausea and vomiting.
More details

This study is evaluating the feasibility of accelerated partial breast irradiation (APBI) in women with breast cancer.
More details

A phase 3 study looking at the effectiveness of treatment NKTR-102 in patients with metastatic breast cancer who have stable brain metastases and have previously been treated with an Anthracycline, a Taxane, and Capecitabine.
More details

This is a proof-of-concept pilot study to determine if short-term treatment with Denosumab is a feasible chemoprevention option against breast cancer for BRCA1 and BRCA2 mutation carriers, as well as high risk, non-BRCA carriers.
More details

This is a phase 1 trial looking at CPI-444, a new drug that targets the adenosine-A2A receptor.
More details

You can join this phase 3 study if you have diagnosed with early invasive breast cancer and you have had or will have surgery for this, and you also plan have chemotherapy as part of your anti-cancer treatment.
More details

The purpose of this open-label, 2:1 randomized Phase III trial is to compare the safety and efficacy of BMN 673 versus protocol-specific physician's choice in patients who have locally advanced and/or metastatic breast cancer with germline BRCA mutations.
More details

This phase 1b study will determine the safety and efficacy of the combined treatment of Abraxane and phenelzine sulfate (Nardil) for metastatic or locally advanced breast cancer.
More details

This phase 2 study looks at the effectiveness of Tucatinib vs a placebo in combination with Capecitabine and Trastuzumab in patients with pretreated unresectable locally advanced or metastatic HER2+ breast cancer
More details

Phase 1 open-label, dose escalation study of INB03 in patients with metastatic cancer with increased inflammatory biomarkers in peripheral blood.
More details

This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with locally advanced or metastatic solid tumors.
More details

The purpose of this trial is to inform the future clinical development of the two investigational agents in ER+ breast cancer, LEE011 (CDK4/6 inhibitor) and BYL719 (PI3K-alpha inhibitor).
More details

Lifepool is a research resource for study into breast cancer and women's health. It aims to recruit 100,000 Australian women. This will establish one of the largest cohorts in the world, providing research tools to answer critical questions about breast cancer. Lifepool aims to gather information on health and lifestyle, mammogram data and asks permission to track the health of each participant through linkage with other health databases.
More details

A phase 2 study of local therapy (stereotactic radiosurgery and/or surgery) for treatment of up to 5 brain metastases from HER2 positive breast cancer.
More details

This phase II study is testing whether MCS110 antibody therapy improves the efficacy of carboplatin and gemcitabine, for patients with advanced triple negative breast cancer.
More details

The primary purpose of this study is to determine the feasibility of using cardiac MRI scans, cardiac ultrasound and blood tests to detect changes in heart function following completion of chemotherapy and/or radiation therapy for cancer.
More details

Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer
More details

A phase 2 exploratory, open-label, single arm study of BYL719 Monotherapy, a selective Phosphatidylinositol 3-kinase (PI3K) Alpha Inhibitor, in adult patients with ABC progressing after first line therapy.
More details

This study is for women with ER+ breast cancer who want to interrupt endocrine therapy in order to become pregnant.
More details

An open-label, randomized, window of opportunity study between diagnosis and definite surgery, to assess the effect of antiestrogen therapies, alone and in combination with microionized progesterone (prometrium) in patients with newly diagnosed ER+PR+ breast cancer.
More details

A single arm phase II study using magnetic resonance imaging (MRI) to select patients with early breast cancer for omission of post-operative radiotherapy.
More details

This Phase II study is evaluating the safety and effectiveness of Stereotactic Ablative Body Radiotherapy (SABR) for the treatment of lung tumours. You may be eligible to join this study if: you are aged 18 years or above; have 1-3 lung metastases from any non-haematological primary tumour; you are medically inoperable, high risk or have decline surgery; and you have not had any previous high-dose radiotherapy to the chest region
More details

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.
More details

This study is exploring the effectiveness and safety of a new treatment in patients with advanced breast cancer.
More details

This research is to find out more about the effects of menopause after removal of the ovaries and how that may impact on a woman’s life. This information will then be used to inform health care for other women who decide to have this surgery.
More details

A phase II study evaluating the efficacy and safety of Ipilimumab and Nivolumab with neoadjuvant weekly paclitaxel after anthracycline-based chemotherapy in high-risk primary triple negative breast cancer, followed by definitive surgery and one-year total duration of Nivolumab.
More details